DURECT Corp (DRRX.OQ)
DRRX.OQ on NASDAQ Stock Exchange Global Market
1.50USD
4:00pm EDT
1.50USD
4:00pm EDT
Change (% chg)
$-0.06 (-3.85%)
$-0.06 (-3.85%)
Prev Close
$1.56
$1.56
Open
$1.57
$1.57
Day's High
$1.57
$1.57
Day's Low
$1.41
$1.41
Volume
137,259
137,259
Avg. Vol
188,290
188,290
52-wk High
$2.55
$2.55
52-wk Low
$0.75
$0.75
About
Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY... (more)
Overall
| Beta: | 1.81 |
| Market Cap(Mil.): | $299.88 |
| Shares Outstanding(Mil.): | 147.00 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| DRRX.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 85.36 | 32.76 |
| EPS (TTM): | -0.25 | -- | -- |
| ROI: | -109.40 | 2.21 | 14.61 |
| ROE: | -411.96 | 3.85 | 16.34 |
BRIEF-Durect Announces Amendment To Licensing Agreement With Sandoz
* DURECT ANNOUNCES AMENDMENT TO LICENSING AGREEMENT WITH SANDOZ RELATED TO POSIMIR® (SABER®-BUPIVACAINE)
BRIEF-Durect Corporation Q1 Loss Per Share $0.05
* DURECT CORPORATION ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
BRIEF-Durect Announces FDA Advisory Committee Meeting For Remoxy Er
* DURECT ANNOUNCES FDA ADVISORY COMMITTEE MEETING FOR REMOXY® ER
BRIEF-Durect Corporation Qtrly Earnings Per Share $0.05
* ORATION ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND UPDATE OF PROGRAMS
BRIEF-Durect Corp Says Commenced Patient Dosing In A Phase 2A Clinical Trial Of Dur-928
* DURECT CORP SAYS COMMENCED PATIENT DOSING IN A PHASE 2A CLINICAL TRIAL OF DUR-928 IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS (PSC) - SEC FILING
Competitors
| Price | Chg | |
|---|---|---|
| Hisamitsu Pharmaceutical Co Inc (4530.T) | ¥8,460 | -- |
| Johnson & Johnson (JNJ.N) | $127.80 | -1.31 |
| Pfizer Inc. (PFE.N) | $37.66 | +0.01 |
| Novartis AG (NOVN.S) | CHF80.66 | +2.46 |
| AstraZeneca plc (AZN.L) | 5,606.00 | +55.00 |
| Eli Lilly And Co (LLY.N) | $90.03 | +0.46 |
| Kimberly Clark Corp (KMB.N) | $103.90 | -2.57 |
| Bristol-Myers Squibb Co (BMY.N) | $56.88 | +0.25 |
| Bristol-Myers Squibb Co (BMYMP.PK) | $950.15 | -- |
| Covidien Ltd (COV.N) | -- | -- |
Estimates